Filing Details

Accession Number:
0001062993-23-019205
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-10 17:04:11
Reporting Period:
2023-10-09
Accepted Time:
2023-10-10 17:04:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1042074 Cymabay Therapeutics Inc. CBAY Pharmaceutical Preparations (2834) 943103561
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1588861 Sujal Shah C/O Cymabay Therapeutics, Inc.
7575 Gateway Blvd., Suite 110
Newark CA 94560
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-09 64,861 $5.00 236,162 No 4 M Direct
Common Stock Disposition 2023-10-09 64,861 $14.20 171,301 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2023-10-09 31,034 $0.00 31,034 $5.00
Common Stock Stock Appreciation Right Disposition 2023-10-09 12,972 $0.00 12,972 $5.00
Common Stock Employee Stock Option (right to buy) Disposition 2023-10-09 20,855 $0.00 20,855 $5.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
62,072 2023-12-22 No 4 M Direct
25,945 2023-12-22 No 4 M Direct
41,711 2024-01-05 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.07 to $14.35, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter.
  4. The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date.
  5. The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months.